Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Saved in:
| Title: | Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. |
|---|---|
| Authors: | Bolton AE; Novartis Pharma AG, Basel, Switzerland. ann.bolton@pharma.novartis.com, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U, Seiberling M |
| Source: | Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2004 Feb; Vol. 53 (2), pp. 102-6. Date of Electronic Publication: 2003 Nov 07. |
| Publication Type: | Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0344-5704 (Print) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 14605865 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Bolton+AE%22">Bolton AE</searchLink>; Novartis Pharma AG, Basel, Switzerland. ann.bolton@pharma.novartis.com<br /><searchLink fieldCode="AU" term="%22Peng+B%22">Peng B</searchLink><br /><searchLink fieldCode="AU" term="%22Hubert+M%22">Hubert M</searchLink><br /><searchLink fieldCode="AU" term="%22Krebs-Brown+A%22">Krebs-Brown A</searchLink><br /><searchLink fieldCode="AU" term="%22Capdeville+R%22">Capdeville R</searchLink><br /><searchLink fieldCode="AU" term="%22Keller+U%22">Keller U</searchLink><br /><searchLink fieldCode="AU" term="%22Seiberling+M%22">Seiberling M</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%227806519%22">Cancer chemotherapy and pharmacology</searchLink> [Cancer Chemother Pharmacol] 2004 Feb; Vol. 53 (2), pp. 102-6. <i>Date of Electronic Publication: </i>2003 Nov 07. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>7806519 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>0344-5704 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203445704%22">03445704 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Chemother Pharmacol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=14605865 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s00280-003-0722-9 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 102 Titles: – TitleFull: Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Bolton AE – PersonEntity: Name: NameFull: Peng B – PersonEntity: Name: NameFull: Hubert M – PersonEntity: Name: NameFull: Krebs-Brown A – PersonEntity: Name: NameFull: Capdeville R – PersonEntity: Name: NameFull: Keller U – PersonEntity: Name: NameFull: Seiberling M IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 02 Text: 2004 Feb Type: published Y: 2004 Identifiers: – Type: issn-print Value: 0344-5704 Numbering: – Type: volume Value: 53 – Type: issue Value: 2 Titles: – TitleFull: Cancer chemotherapy and pharmacology Type: main |
| ResultId | 1 |
